Our Products

Focusing on the diabetes as the core therapeutic field, Fosun Wanbang Pharma Group has established a core competitive advantage in R&D, production and sales in the field of "four high one anti" (hyperglycemia, hypertension, hyperlipidemia, hyperuricemia and anti-tumor).

DiabetesCardiovascularAntitumorMetabolism and Digestion
NephropathyOther FieldsActive Pharmaceutical Ingredients

19

No.1 Domestic Market Share (IQVIA data)

120

+

New Development Projects

23

Products with Annual Sales Exceeding 100 Million RMB

Diabetes

Wansuping® ranked first in the domestic sales of Glimepiride Tablets, was awarded the title of "People's Assured Medicine" by the health newspaper, and won the Outstanding Endocrine Brand Award for 5 consecutive years.

Metabolism and Digestion

Ke Yi® (New Compound Aloe Capsule) was awarded the "Gold Award in the 2019 [ Healthy China • Brand List ]".

Cardiovascular

Products cover blood pressure, blood lipids, anticoagulation, antithrombotic and other fields. among which, Bang Zhi is the first pitavastatin in China to submit a consistency evaluation.

Antitumor

Zhao Hui Xian® is the first to file generic product of Bicalutamide Tablets in China, and has been rated as a Shanghai Star Product for many years.

Nephropathy

Yi Bao®, as the only product with independent whole cold chain transportation, has been included in the national Class B medical insurance.

Other Fields

We actively explore new therapeutic fields, and through unremitting professional accumulation, we provide innovative products and professional services in every therapeutic field that we enter.

Active Pharmaceutical Ingredient (API)